$EQ

Zedelmayer Christine sold $542 of EQ

Zedelmayer Christine (Sr. Vice President and COO) sold 200 shares of Equillium, Inc. (EQ) at $2.71 on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zedelmayer Christine
Published May 29, 2026, 10:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EQ
Neutral
medium confidence
Mentioned
$EQ
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EQNeutralLow
01

Why it matters

The disclosure provides transparency on insider liquidity but does not, by itself, indicate a new fundamental development given the stated pre-arranged 10b5-1 plan.

02

Market read

Traders may log the event for sentiment/positioning, but it is unlikely to drive a standalone price move.

03

What to watch

The dollar amount is small relative to typical institutional flows; without additional insider buys/sells or corporate news, the signal-to-noise is low.

Relevance 4/10Novelty 2/10Timing: SEC Form 4 filed after-hours (2026-05-29) for a trade dated 2026-05-28

Background

This is an SEC Form 4 insider transaction: officer/direct holdings change disclosed for Equillium, Inc.

Company-level read

Ticker impact

$EQNeutralMedium confidence
Context

Equillium COO sold 200 shares in an open-market transaction under a pre-arranged 10b5-1 plan, disclosed via SEC Form 4.

Expected impact

Likely limited near-term impact; any reaction should be muted unless accompanied by other news.

Evidence & confidence

The filing specifies an open-market sale and a pre-arranged 10b5-1 plan, reducing the likelihood of information leakage or urgent negative news.

Market effects

Minimal—single-company insider disclosure without accompanying operational/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with internal confidence gaps; traders may still watch for follow-on insider activity or changes in trading patterns.

Key entities

  • Equillium, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Christine Zedelmayer

    COO and Sr. Vice President who sold 200 shares.

Related articles

$EQMedAI 8/10

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium (NASDAQ:EQ) presented preclinical data linking aryl hydrocarbon receptor (AhR) activation to miR-124 induction, led by CSO Stephen Connelly. Using its AhR modulator EQ504 and Abivax’s obefazimod (ABX464), the company reported miR-124 induction in immune cells with AhR antagonism reducing it, alongside decreases in pro-inflammatory cytokines. ABX464 showed an AhR EC50 ~400 nM in reporter assays. Equillium said Phase 1 readouts will focus on colon tissue drug exposure (EC50–EC90) and CYP